期刊
CEREBRAL CORTEX
卷 22, 期 9, 页码 1993-2004出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cercor/bhr271
关键词
A beta; FDG-PET; MCI; PIB-PET
资金
- Merck
- Avid
- National Institutes of Health
- DOD
- Veterans Affairs
- Elan/Wyeth Alzheimer's Immunotherapy Program North American Advisory Board
- Alzheimer's Association
- Forest, University of California, Davis
- Tel-Aviv University Medical School
- WennerFoundation
- Gren Foundation
- Social Security Administration
- Korean Neurological Association
- Washington University at St Louis
- Banner Alzheimer's Institute
- Clinical Trials on Alzheimer's Disease
- Veterans Affairs Central Office
- Beijing Institute of Geriatrics
- Innogenetics
- New York University, NeuroVigil, Inc.
- CHRU-Hopital Roger Salengro
- Siemens
- AstraZeneca
- Geneva University Hospitals
- Lilly
- University of California
- San Diego-ADNI
- Paris University
- Institut Catala de Neurociencies Aplicades
- University of New Mexico School of Medicine
- Ipsen
- Pfizer
- AD PD meeting
- Paul Sabatier University
- Novartis
- Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health) [U01 AG024904]
- Colloquium Paris
- National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
- Abbott
- AstraZeneca AB
- Bayer Schering Pharma AG
- Bristol-Myers Squibb
- Eisai Global Clinical Development
- Elan Corporation
- Genentech
- GE Healthcare
- GlaxoSmithKline
- Johnson and Johnson
- Eli Lilly and Co.
- Medpace, Inc.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc
- F. Hoffman-La Roche
- Schering-Plough
- Synarc, Inc.
- Alzheimer's Association and Alzheimer's Drug Discovery Foundation
- US Food and Drug Administration
- Foundation for the National Institutes of Health
- National Institutes of Health [P30 AG010129, K01 AG030514]
- Dana Foundation
- Alzheimer's Drug Discovery Foundation
- Anonymous Foundation
- Bayer Healthcare
- BioClinica, Inc. (ADNI 2)
- Cure Alzheimer's Fund
- Eisai
- Elan
- Gene Network Sciences
- Johnson Johnson
- Eli Lilly Company
- Medpace
- Roche
- Schering Plough
- Synarc
- Wyeth
Beta-amyloid (A beta) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of A beta in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low A beta levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of A beta. In subjects with mild cognitive impairment, increased brain A beta levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between A beta and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high A beta levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low A beta. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high A beta years before the onset of dementia but also that HC with substantial A beta levels show higher A beta pathology resistance, lack other pathologies that condition neurotoxic effects of A beta, or accumulated A beta for a shorter time period.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据